GSK’s PD-1 drug Jemperli performs so well in the endometrial cancer RUBY study it might even get a chance to become the backbone treatment!
A couple of days ago (16th March 2024), GSK posted absolutely excellent data on their PD-1 drug Jemperli (dostarlimab) at a […]
Read More